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S262 Poster Session Imalignant group, the cumulative incidence of 90% donor chimerism
at +100 days was only 64.6%, and the percentage of full or mixed chi-
merism at one year was 76% and 24%. Our data show that while
RIC-HSCT leads to durable and full donor chimerism in the major-
ity of patients, some experience engraftment instability, which could
respond to timely intervention with withdrawal of immune suppres-
sion and/or DLI. Frequent and long-term monitoring of donor chi-
merism would offer the opportunity to positively impact the clinical
course of these patients.
Table 1. Patient Characteristics (n588)Median Age7
57.3 years
(20 days - 21 years)M/F 47/41
Diagnoses
Malignant 40
ALL/AML/MDS 13/4/7
CML 5
Relapsed HD 3
Other 8
Non-malignant 48
SCID 13
SAA 7
Other 28
HPC Source
Matched Sibling/Related 34
MUD/MM Related 22
MMUD 32
PBSC/Marrow/Cord 74/2/12
Median Cell Dose
CD 34+/Kg  10^6 (0.12 - 37.5)
MNC/Kg  10^8 (0.27 - 9.5)
Conditioning Regimen
Fludarabine/Busulfan/ATG 57
Fludarabine/Busulfan/ECP 19
Fludarabine/Busulfan 5
Other fludarabine 7296
CLINICAL RELEVANCE OF SERIAL CHIMERISM ANALYSIS AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN
WITH NON-MALIGNANT DISEASES
Park, M., Koh, K.N., Kim, B.E., Choi, E.S., Shin, H., Im, H.J., Seo, J.J.
Asan Medical Center Children’s Hospital, University of Ulsan College of
Medicine, Seoul, Korea
Background: In allogeneic hematopoietic stem cell transplantation
(HSCT), the effect of chimerism often remains unclear andmay have
different implications in various diseases. We performed retrospec-
tive study to evaluate chimerism status and transplant outcome in
children with non-malignant diseases.
Patients & Methods: Between September 1999 and January 2010
we analyzed the data of 42 transplants performed in 40 children
with nonmalignant diseases. Short tandem repeat polymerase chain
reaction (STR-PCR) was used to evaluate chimerism. Mixed chime-
rism (MC) was defined as . 1% recipient cells.
Results:MCwas detected in 17 (40%) transplants. Of these 17 cases,
8 developed decreasingMC, 6 persisted with low-proportions of au-
tologous cells below 30% (stable MC) and 3 showed $ 30% recipi-
ent signals in two consecutive samples (high MC). Among 4 graft
failures, one showed autologous recovery. The 2 patients with graft
failure received the second transplant, of whom one is alive in remis-
sion. The remaining one received donor lymphocyte infusion (DLI)
due to the high MC, which subsequently resulted in further increase
of autologous cells. The incidence of MC was not different statisti-
cally between reduced intensity conditioning andmyeloablative con-
ditioning. The probabilities of achieving complete donor chimerism
(CC) at 1, 3, 6 and 12 months after HSCT were 70.0%, 68.3%,
75.7% and 78.8%, respectively. Overall probability of grade II–IV
acute GVHD was significantly higher in CC group compared to
the MC group (57.1% vs. 11.8%, p 5 0.006). High MC was associ-
ated with graft failure (p 5 0.004). At a median follow-up of 36
months, the 3-year overall survival and event-free survival after
HSCT for non-malignant diseases in children were 90.0% and87.2%, respectively. There was no significant survival difference be-
tween CC and MC. Patients with high MC showed inferior survival
rate compared to the patients with stable or decreasing MC (33.3 vs.
92.3%, p 5 0.014).
Conclusions: In this study, overall incidence of MC was 40% after
transplantation for non-malignant diseases.MCmay indicate a toler-
ant state in transplanted individuals with a decreased incidence of
acute GVHD. However, high MC was at risk of graft failure and
also associated with lower survival rate. Sequential chimeric status
could give important information on post-transplant course after
HSCT for non-malignant diseases.297
FOLINIC ACID RESCUE INCREASES ABILITY TO DELIVER FULL COURSE OF
METHOTREXATE GVHD PROPHYLAXIS FOR PEDIATRIC HSCT RECIPI-
ENTS
Hudspeth, M., Heath, T., Chiuzan, C., Garrett-Mayer, E., Nista, E.,
Burton, L., Ragucci, D. Medical University of South Carolina, Charleston,
SC
Background: Cyclosporine and short-course MTX are commonly
used for GVHD prophylaxis in pediatric BMT. Day 11 MTX has
been administered to\ 75 % of patients in adult studies due to se-
vere mucositis or organ dysfunction. Omission of day 11 MTX is as-
sociated with an increased risk of GVHD. Folinic acid may
ameliorate MTX toxicity.
Methods:We conducted a retrospective chart review of all pediatric
patients from January 2000- July 2010 who received cyclosporine
and short course MTX for GVHD prophylaxis. One patient was ex-
cluded formissing records. Patients prior to July 2007 did not receive
folinic acid (N 5 18). All patients thereafter received folinic acid 10
mg/m2 IV 12 hours after each MTX dose (N5 29). Logistic regres-
sion was used to estimate the ORmeasuring the association between
folinic acid use and receipt of day 11MTX, adjusting for preparative
regimen, graft source, and disease status at BMT. Kaplan-Meier sur-
vival curves with a log-rank test were used to determine relapse-free
survival. Statistical significance was accepted at p\ 0.05.
Results: Patients who received folinic acid rescue were significantly
more likely to receive day 11MTX.(OR 10.42, 95%CI 1.21-262.27)
However, there was no significant difference inGrade III-IVGVHD
between the patients who received folinic acid rescue and those who
did not. (OR 1.15, 95% CI 0.08-18.14). Folinic acid rescue did not
impact relapse-free survival (P 5 0.82).
Conclusion:Although folinic acid rescue increased the likelihood of
receiving the day 11 MTX, this did not translate into a reduction of
Grade III-IV GVHD. However, there was also no difference in re-
lapse-free survival to suggest a deleterious effect on disease control,
which has been cited as a concern by some groups. Increased likeli-
hood of receiving day 11MTX does suggest that folinic acid amelio-
rates MTX toxicity, such as severe mucositis. Folinic acid rescue for
short course MTX should be studied in a prospective, randomized
fashion.298
DIGITAL MULTIPLEXED QUANTIFICATION OF BOTH T-CELL RECEPTOR
b-CHAIN AND a-CHAIN DIVERSITY IN T CELLS USING THE NANOSTRING
NCOUNTER ASSAY SYSTEM
Maiti, S.N.1, Zhang, M.2, Bernatchez, C.2, Torikai, H.1, Kellar, D.1,
Gibbons, H.1, Hernandez, J.2, Andersson, H.1, Huls, H.1, Lee, D.1,
Hwu, P.2, Radvanyi, L.2, Cooper, L.1 1M.D. Anderson Cancer Center,
Houston, TX; 2M.D. Anderson Cancer Center, Houston, TX
Measurement and skewing ofT-cell receptor (TCR)a and b diver-
sity in the tumor-bearing host (i) engrafted with allogeneic hemato-
poietic stem cells and/or (ii) after vaccination or adoptive T-cell
transfer, are used for monitoring the effect of immunotherapies.
TCR diversity is mostly concentrated within the third complemen-
tarity-determining region (CDR3) of a and b chains. Currently avail-
able methods for measuring diversity are primarily limited to
TCRVb usage and are (i) flow-cytometric detection by using
